Prosight Management, LP Assembly Biosciences, Inc. Transaction History

Prosight Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.13 - $3.46 $565,800 - $919,093	-265,634 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.14 - $3.9 $365,948 - $454,521	116,544 Added 78.17%	265,634 $924,000
Q2 2021 Aug 13, 2021	BUY	$3.8 - $4.56 $351,842 - $422,210	92,590 Added 163.88%	149,090 $578,000
Q1 2021 May 14, 2021	BUY	$4.33 - $6.63 $244,645 - $374,595	56,500 New	56,500 $260,000
Q3 2019 Nov 14, 2019	SELL	$9.83 - $14.82 $1.97 Million - $2.96 Million	-200,000 Closed	0 $0

Q2 2019 Aug 14, 2019	SELL	$12.9 - $20.8 $1.48 Million - $2.38 Million	-114,410 Reduced 36.39%	200,000 $2.7 Million
Q1 2019 May 15, 2019	BUY	$17.7 - $24.93 $680,901 - $959,032	38,469 Added 13.94%	314,410 $6.19 Million
Q4 2018 Feb 14, 2019	BUY	$19.05 - $36.45 $2.98 Million - $5.7 Million	156,363 Added 130.76%	275,941 $6.24 Million
Q3 2018 Nov 15, 2018	BUY	$34.41 - $44.23 $1.87 Million - $2.4 Million	54,277 Added 83.12%	119,578 $4.44 Million
Q2 2018 Aug 14, 2018	BUY	$39.21 - $50.29 $2.56 Million - $3.28 Million	65,301 New	65,301 $2.56 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.